Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioNTech SEBNTX · Entity 3181 | Chief Commercial Officer | May 12, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioNTech SE
Report date May 12, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Expires 2036-05-12 | Direct | 12,586 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 12,586 · Balance 12,586 F1: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price. F2: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. F3: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-05-12 | Direct | 10,069 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 10,069 · Balance 10,069 F4: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
F2: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
F3: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
F4: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 13, 2026 20:02 UTC | BioNTech SE BNTX · Entity 3181 | GrantPerformance Share Unit · Derivative | 10,069 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002118987-26-000002 · wk-form4_1778702527.xml · derivative · entry 2 Hanekamp Annemarie · CIK 0002118987 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,069 Underlying: Ordinary Shares · 10,069 shares Expires 2036-05-12 F4 · derivative.exercise_date: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date. F4 · derivative.underlying: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:02 UTC | BioNTech SE BNTX · Entity 3181 | GrantOption (right to buy) · Derivative | 12,586 | $0.00 | $0.00 |
DisclosureSEC source: 0002118987-26-000002 · wk-form4_1778702527.xml · derivative · entry 1 Hanekamp Annemarie · CIK 0002118987 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,586 Underlying: Ordinary Shares · 12,586 shares Expires 2036-05-12 F1 · derivative.exercise_price: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price. F2 · derivative.exercise_date: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. F3 · derivative.underlying: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.